REPHUnknown
Recro Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Recro Pharma, Inc. (REPH), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are REPH insiders buying or selling?
Recro Pharma, Inc. insiders reported 8 open-market buys ($370.6K) and 12 sells ($5.4M) across 20 Form 4 filings — a net selling position of $5.0M.
Source: SEC EDGAR Form 4
Key Statistics (as of Mar 17, 2022)
Total Form 4 filings
20
SEC EDGAR
Insider filers
9
Insider buys (8)
$370.6K
Insider sells (12)
$5.4M
Insider sentiment
Net sellingNet insider flow of $5.0M in net selling.
Recent REPH insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 17, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 512 | $1.96 | $1.0K |
| Feb 17, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 571 | $1.77 | $1.0K |
| Jan 19, 2022 | David J Enloe JR | Chief Executive Officer | Purchase | 602 | $1.68 | $1.0K |
| Dec 23, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 99.4K | $1.55 | $154.2K |
| Dec 20, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 50.0K | $1.61 | $80.5K |
| Dec 18, 2021 | David J Enloe JR | Chief Executive Officer | Purchase | 617 | $1.61 | $993.37 |
| Dec 15, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 50.6K | $1.62 | $81.8K |
| Nov 19, 2021 | James Charles Miller | Director | Purchase | 1.0K | $1.69 | $1.7K |
| Nov 16, 2021 | Ryan David Lake | Chief Financial Officer | Purchase | 1.2K | $1.65 | $2.0K |
| Nov 16, 2021 | David J Enloe JR | Chief Executive Officer | Purchase | 1.7K | $1.68 | $2.9K |
| Jun 14, 2021 | AWM Investment Company, Inc. | 10% Owner | Sale | 466.7K | $2.21 | $1.0M |
| Dec 29, 2020 | SCP Vitalife Partners (Israel) II, L.P. | 10% Owner | Sale | 18.8K | $3.17 | $59.7K |
| Dec 29, 2020 | SCP Vitalife Partners II LP | 10% Owner | Sale | 56.4K | $3.17 | $178.7K |
| Dec 23, 2020 | SCP Vitalife Partners (Israel) II, L.P. | 10% Owner | Sale | 6.2K | $3.03 | $18.8K |
| Dec 23, 2020 | SCP Vitalife Partners II LP | 10% Owner | Sale | 18.6K | $3.03 | $56.3K |
| Apr 20, 2020 | Geraldine Henwood | President and CEO | Sale | 80.0K | $8.22 | $657.6K |
| Apr 20, 2020 | Geraldine Henwood | President and CEO | Sale | 80.0K | $8.22 | $657.6K |
| May 21, 2019 | Arnaud Ajdler | Director | Purchase | 40.0K | $9.00 | $360.0K |
| May 15, 2019 | Geraldine Henwood | President and CEO | Sale | 144.8K | $8.89 | $1.3M |
| May 24, 2018 | Broadfin Healthcare Master Fund Ltd | 10% Owner | Sale | 188.0K | $5.81 | $1.1M |
Showing the 20 most recent of 20 Form 4 filings for Recro Pharma, Inc..
Most active REPH insiders
- David J Enloe JR5 filings
- AWM Investment Company, Inc.4 filings
- Geraldine Henwood3 filings
- SCP Vitalife Partners (Israel) II, L.P.2 filings
- SCP Vitalife Partners II LP2 filings
Ask anything about REPH insider activity
Use Trabud's AI agent to query Recro Pharma, Inc.'s Form 4 history in plain English — "Show me REPH CEO purchases this year" or compare it against any other ticker.
Open the AI agentREPH insider trading FAQ
Are Recro Pharma, Inc. insiders buying or selling?
Across 20 SEC Form 4 filings, Recro Pharma, Inc. (REPH) insiders reported 8 open-market purchases totaling $370.6K and 12 sales totaling $5.4M. That is a net selling position of $5.0M.
How many insiders trade REPH stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Recro Pharma, Inc.. The most recent filing was accepted on Mar 17, 2022.
Where does Trabud get REPH insider trading data?
All REPH insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.